Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Pharus Taiwan Inc. manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. Currently, the portfolio contains 2 pending office actions. These actions are located in 2 distinct art units, which implies that the company's intellectual property is being examined across different specialized divisions within the patent office.
There are 2 distinct examiners involved in the prosecution of this portfolio. LUO, JAMMY NMN is the busiest examiner, currently responsible for 1 busiest examiner pending office action. Since there are 2 pending office actions and 2 distinct examiners, each examiner is managing exactly one case, resulting in an even distribution of the active workload.
For a practitioner, the involvement of 2 distinct art units and 2 distinct examiners within Biotechnology & Pharmaceuticals necessitates a tailored approach for each case. The firm must monitor the specific trends of both art units while engaging with LUO, JAMMY NMN and the other examiner. This 2-action workload is small but diversified, requiring the practitioner to stay informed on the procedural nuances of two different examination environments.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LUO, JAMMY NMN | 1 | — | — |
| ANDERSON-FEARS, KEENAN NEIL | 1 | 12.0% | +41.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17544947 | EARLY DETECTION AND PREDICTION METHOD OF PAN-CANCER | ANDERSON-FEARS, KEENAN NEIL | 45d overdue |
| 18305396 | CANCER EARLY DETECTION METHOD USING LIQUID BIOPSY | LUO, JAMMY NMN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17544947 | EARLY DETECTION AND PREDICTION METHOD OF PAN-CANCER | ANDERSON-FEARS, KEENAN NEIL | 45d overdue |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| 1687 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18305396 | CANCER EARLY DETECTION METHOD USING LIQUID BIOPSY | LUO, JAMMY NMN | 1682 | §101§103 | Non-Final OA | — | Pending | Apr 24, 2023 |
| 17544947 | EARLY DETECTION AND PREDICTION METHOD OF PAN-CANCER | ANDERSON-FEARS, KEENAN NEIL | 1687 | §101§103 | Final Rejection | 45d overdue | Pending | Dec 08, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial